



Australian Government

Patent Office
Canberra

I, LEANNE MYNOTT, MANAGER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. PQ 1999 for a patent by THE UNIVERSITY OF MELBOURNE as filed on 03 August 1999.

I further certify that pursuant to the provisions of Section 38(1) of the Patents Act 1990 a complete specification was filed on 1 August 2000 and it is an associated application to Provisional Application No. PQ 1999 and has been allocated No.48971/00.

WITNESS my hand this
Twenty-eighth day of July 2004

LEANNE MYNOTT
MANAGER EXAMINATION SUPPORT
AND SALES



CERTIFIED COPY OF
PRIORITY DOCUMENT

BEST AVAILABLE COPY

The University of Melbourne

A U S T R A L I A
Patents Act 1990

PROVISIONAL SPECIFICATION

for the invention entitled:

"A method of treatment and agents useful for same"

The invention is described in the following statement:

A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME

FIELD OF THE INVENTION

5 The present invention relates generally to a method of modulating bone resorption and to agents useful for same. More particularly, the present invention provides for the use of leptin and its derivatives, homologues, analogues, antagonists or agonists to modulate osteoclastogenesis. Even more particularly, the present invention contemplates the treatment of disorders characterised by or associated with excessive bone resorption such
10 as but not limited to osteoporosis and Paget's disease. The present invention further provides for the use of leptin and its derivatives, homologues, analogues, antagonists and agonists in the manufacture of a medicament for the modulation of bone resorption.

BACKGROUND OF THE INVENTION

15 The subject specification contains nucleotide and amino acid sequence information prepared using the programme PatentIn Version 2.0, presented herein after the bibliography. Each nucleotide or amino acid sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210> 1, <210> 2, etc). The length, type of sequence (DNA, protein (PRT), etc) and source
20 organism for each nucleotide or amino acid sequence are indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively. Nucleotide and amino acid sequences referred to in the specification are defined by the information provided in numeric indicator field <400> followed by the sequence
25 identifier (eg. <400> 1, <400> 2, etc).

The designation of nucleotide residues referred to herein are those recommended by the IUPAC-IUB Biochemical Nomenclature Commission, wherein A represents Adenine, C represents Cytosine, G represents Guanine, T represents thymine, Y represents a
30 pyrimidine residue, R represents a purine residue, M represents Adenine or Cytosine, K represents Guanine or Thymine, S represents Guanine or Cytosine, W represents Adenine

- 2 -

or Thymine, H represents a nucleotide other than Guanine, B represents a nucleotide other than Adenine, V represents a nucleotide other than Thymine, D represents a nucleotide other than Cytosine and N represents any nucleotide residue.

- 5 Bibliographic details of the publications referred to in this specification by author are collected at the end of the description.

The regulation of bone metabolism is a multifaceted process requiring the tight control of bone resorption and bone formation. The latter is the primary function of osteoblasts
10 whereas bone resorption involves osteoclasts.

Osteoclasts are multinucleate cells formed in bone marrow by the fusion of cells from the monocyte/macrophage lineage (Suda *et al*, 1992; Quinn *et al*, 1998). A variety of factors play a role in regulating osteoclast formation including growth factors, systemic hormones
15 and cell contact with marrow stroma.

A number of proteins have been identified which are involved in the process of osteoclastogenesis. Osteoprotegerin, also known as osteoclastogenesis inhibitory factor (OPG and OCIF, respectively), is a secreted member of the TNF receptor superfamily that
20 blocks osteoclast differentiation both *in vitro* and *in vivo* (Yasuda, *et al*, 1998; Simonet *et al*, 1997). The cloning of a membrane bound ligand for OPG (OPG-ligand [OPGL]) resulted in the identification of an essential signal for proliferation and fusion of osteoclast progenitors (Yasuda, *et al*, 1998). This protein, also called osteoclast differentiation factor (ODF), is expressed on the plasma membrane of osteoblasts/marrow stromal cells
25 and has a membrane bound receptor (in contrast to the soluble receptor, OPG/OCIF) identified as receptor activator of NF-kappa β (RANK). OPGL/ODF has also been termed TNF-related activation-induced cytokine (TRANCE) and RANK-ligand (RANKL). The combination of M-CSF and a soluble form of recombinant ODF, lacking the transmembrane domain, is necessary and sufficient to stimulate osteoclast generation, in
30 the absence of osteoblast or stromal cells, from either murine spleen cells or human monocytes (Matsuzaki *et al*, 1998; Quinn *et al*, 1988).

- 3 -

Leptin, a cytokine produced primarily by mature adipocytes, is linked to food intake and energy expenditure (Friedman and Halaas, 1998) but also has activity in neuroendocrine, metabolic, reproductive and haemopoetic pathways (Auwerz and Staels, 1998).

- 5 In work leading up to the present invention, the inventors investigated the role of leptin in the bone microenvironment. The inventors have now identified leptin as a regulator of osteoclastogenesis. This provides the basis for the development of a range of medicaments for modulating bone resorption.

10 SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any

- 15 other element or integer or group of elements or integers.

One aspect of the present invention contemplates a method of modulating bone resorption in a human or animal, said method comprising administering to said human or animal an effective amount of leptin or a derivative, homologue, analogue, chemical equivalent,
20 antagonist or agonist thereof for a time and under conditions sufficient for the modulation of osteoclastogenesis.

- Another aspect of the present invention provides a method for inhibiting, reducing or otherwise delaying onset or progression of bone resorption in a human or animal, said
25 method comprising administering to said human or animal an effective amount of a leptin as hereinbefore defined for a time and under conditions sufficient to inhibit, reduce or otherwise delay onset or progression of osteoclastogenesis.

- Yet another aspect of the present invention is directed to the use of leptin as hereinbefore
30 defined in the manufacture of a medicament in the treatment of a disease condition involving excess bone resorption.

Still yet another aspect of the present invention provides a composition useful in the modulation of bone resorption comprising leptin as hereinbefore defined and one or more pharmaceutically acceptable carriers and/or diluents.

5 BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a photographic representation showing generation of TRAP +ve multinuclear cells (MNC) and monoclear (Mono) cells. A colour version of this figure is available by request from the applicant.

10

Figure 2 is a graphical representation showing the effect of leptin on the generation of TRAP +ve multinuclear (MNCs). TRAP +ve MNCs were generated on bone slices from PBMCs treated with ODF (55 ng/ml) and M-CSF (25 ng/ml) for 21 days. a, b, c denote significant difference, $p > 0.05$, ANOVA, Fischers multiple comparison.

15

Figure 3 is a graphical representation showing the effect of leptin on bone resorption by ODF/M-CSF generated human osteoclasts. The percentage of bone surface resorbed by human osteoclast generated from PBMCs was quantified by SEM. a, b, c denotes significant difference, $p > 0.05$, ANOVA, Fischer's multiple comparison.

20

Figure 4 shows photographic and graphical representations of the effects of leptin on OPG and RANK mRNA expression. Adherent PBMCs were treated with leptin for 24 h immediately after settlement. The expression of OPG, RANK and GAPDH mRNA in human PBMCs was quantified using semi-quantitative RT-PCR (A). The net intensity of
25 OPG and RANK product bands of mRNA expression were analysed and corrected for GAPDH (B).

Figure 5 is a graphical representation of the effect of leptin on osteoclastogenesis in purified CD14+ cells. CD14+ cells were positively selected from unfractionated PBMCs
30 using anti-CD14 antibody labelled immunomagnetic beads and cultured on bone slices for 3 weeks in the presence of M-CSF (25 ng/ml) and ODF (40 ng/ml) with and without

- 5 -

leptin 1.6 $\mu\text{g/ml}$.

Figure 6 is a schematic representation of the proposed mechanism of leptin inhibition of osteoclastogenesis. Not shown on the figure is the likely production of leptin by bone
5 marrow adipocytes.

Abbreviations used in the subject specification are defined in Table 1.



- 6 -

TABLE 1

ABBREVIATIONS	
TNF	Tumour necrosis factor
5 OPG (OCIF)	Osteoprotegerin; Osteoclastogenesis inhibitory factor
OPGL (ODF)	Membrane bound ligand for OPG; osteoclast differentiation factor (same as TRANCE, TNF-related activation-induced cytokine)
RANKL	Ligand for RANK (same as OPGL/ODF/TRANCE)
RANK	Receptor activator of NF-kappa β
M-CSF	Macrophage-colony stimulating factor
10 Mono	Mononuclear cell
MNC	Multinuclear cell
TRAP	Tartrate-resistant acid phosphatase
PBMC	Peripheral blood mononuclear cell
PBS	Phosphate buffered saline
15 FCS	Fetal calf serum
TGF β	Transforming growth factor - β
RT-PCR	Reverse transcriptase polymerase chain reaction
CTR	Calcitonin receptor

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated in part on the identification of leptin as a potent inhibitor of osteoclastogenesis. This provides a means for modulating bone resorption.

5

Accordingly, one aspect of the present invention contemplates a method of modulating bone resorption in a human or animal, said method comprising administering to said human or animal an effective amount of leptin or a derivative, homologue, analogue, chemical equivalent, antagonist or agonist thereof for a time and under conditions

10 sufficient for the modulation of osteoclastogenesis.

Reference herein to "leptin" includes reference to a polypeptide having the amino acid sequence set forth in <400>7 or an amino acid sequence having at least 60% similarity thereto while retaining leptin activity or antagonist activity as well as a molecule encoded

15 by the nucleotide sequence set forth in <400>8 or a nucleotide sequence having at least about 60% similarity thereto or a nucleotide sequence capable of hybridising to <400>8 under low stringency conditions at 42°C.

Reference herein to a low stringency at 42°C includes and encompasses from at least about

20 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for

25 hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.

In general, washing is carried out $T_m = 69.3 + 0.41 (G+C)\%$ (Marmur and Doty, 1962).

30 However, the T_m of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatch base pairs (Bonner and Laskey, 1974).



The term "leptin" is defined herein as including all derivatives, homologues, analogues, chemical equivalents, antagonists and agonists thereof.

The term "derivative" and its plural form includes parts, portions, fragments, regions,
5 fusion molecules, mimotopes and mimetics.

Analogues and mimetics include molecules which contain non-naturally occurring amino acids as well as molecules which do not contain amino acids but nevertheless behave functionally the same as leptin. Natural product screening is one useful strategy for
10 identifying analogues and mimetics. Natural product screening involves screening environments such as bacteria, plants, animals, rainforests, riverbeds, seabeds, aquatic environments, coral and antarctic or arctic environments for naturally occurring molecules which mimic, agonise or antagonise leptin of the present invention. Analogues of leptin contemplated herein include modifications to side chains, incorporation of unnatural amino
15 acids and/or their derivatives during peptide synthesis and the use of crosslinkers and other methods which impose conformational constraints on the peptide molecule or their analogues.

Examples of side chain modifications contemplated by the present invention include
20 modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with
25 pyridoxal-5-phosphate followed by reduction with NaBH_4 .

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

30 The carboxyl group may be modified by carbodimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.



- 9 -

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 5 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. 10 Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate. 15

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or 20 D-isomers of amino acids. A list of unnatural amino acid contemplated herein is shown in Table 2.

TABLE 2

5	Non-conventional	Code	Non-conventional	Code
	amino acid		amino acid	
	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
	aminocyclopropane-	Cpro	L-N-methylasparagine	Nmasn
10	carboxylate		L-N-methylaspartic acid	Nmasp
	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbornyl-	Norb	L-N-methylglutamine	
				Nmgln
	carboxylate		L-N-methylglutamic acid	Nmglu
15	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Das	L-N-methylmethionine	Nmmet
20	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
25	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
30	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug

	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva
	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgab
5	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylassparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylasspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
10	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
15	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
20	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- α -methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cyclododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
25	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylassparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylasspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
30	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser

- 12 -

	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
5	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
10	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyla-naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
15	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylassparagine	Masn
	L- α -methylasspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
20	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
25	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
	L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhph

N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
carbamylmethyl)glycine		carbamylmethyl)glycine	
1-carboxy-1-(2,2-diphenyl-	Nmbc		
ethylamino)cyclopropane			

5

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having $(CH_2)_n$ spacer groups with $n=1$ to $n=6$, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional

10 reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C_α and N_α -methylamino acids, introduction of double bonds between C_α and C_β atoms of amino acids and the formation of cyclic peptides or analogues

15 by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

All these types of modifications may be important to stabilise leptin. This may be important if leptin is used, for example, in the manufacture of a therapeutic composition.

20

The present invention further contemplates chemical equivalents of leptin. Chemical equivalents may not necessarily be derived from leptin itself but may share certain conformational or functional similarities. Alternatively, chemical equivalents may be specifically designed to mimic certain physiochemical properties of the polypeptides.

25 Chemical equivalents may be chemically synthesised or may be detected following, for example, natural product screening.

The term "modulate" means that bone resorption may be stimulated, enhanced or otherwise increased or that it may be inhibited, retarded or otherwise reduced. Reduction in bone

30 resorption is important for disease conditions involving an excess of bone resorption such as osteoporosis or Paget's disease. Preferably, the modulation involves a reduction in bone



resorption.

Accordingly, another aspect of the present invention provides a method for inhibiting, reducing or otherwise delaying onset or progression of bone resorption in a human or
5 animal, said method comprising administering to said human or animal an effective amount of a leptin as hereinbefore defined for a time and under conditions sufficient to inhibit, reduce or otherwise delay onset or progression of osteoclastogenesis.

Yet another aspect of the present invention is directed to the use of leptin as hereinbefore
10 defined in the manufacture of a medicament in the treatment of a disease condition involving excess bone resorption.

Such conditions include osteoporosis and Paget's disease.

15 Accordingly, the present invention provides a composition useful in the modulation of bone resorption comprising leptin as hereinbefore defined and one or more pharmaceutically acceptable carriers and/or diluents.

Preferably, the composition inhibits, reduces or otherwise delays onset or progression of
20 osteoclastogenesis.

The preferred form of a composition is as a pharmaceutical composition.

Compositions suitable for injectable use include sterile aqueous solutions (where water
25 soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions. They are generally stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyoil (for example, glycerol, propylene glycol and liquid polyethylene glycol, and
30 the like), suitable mixtures thereof and vegetable oils. The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for

example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.

- 5 Sterile injectable solutions are prepared by incorporating leptin as hereinbefore defined in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by, for example, filter sterilization by other appropriate means. In the case of sterile powders for the preparation of sterile injectable solutions, a preferred method of preparation includes vacuum drying and freeze-drying
10 which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution.

- When leptin is suitable protected, it may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell
15 gelatin capsule, or it may be compressed into tablets.

- The tablets, troches, pills, capsules and the like may also contain the components as listed hereafter: a binder such as gum, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like;
20 and a lubricant such as magnesium stearate. Any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amount employed. In addition, the active compound(s) may be incorporated into sustained-release preparations and formulations.

- 25 Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated.
30 Supplementary active ingredients can also be incorporated into the compositions.



- 16 -

Effective amounts of leptin will vary depending on the condition to be treated by may range from 0.001 ng/kg body weight to 100 mg/kg body weight. Leptin may be administered every minute or hourly, daily, weekly or monthly. Leptin may be used prophylactically or in the treatment of a disease condition.

5

The mode of administration may be intravenous, drip, infusion, oral, intraperitoneal, intra-bone, parenteral, inhalation, nasal drip, aerosol or rectal.

Methods and pharmaceutical carriers for preparation of pharmaceutical compositions are
10 well known in the art, as set out in textbooks such as Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Company, Easton, Pennsylvania, USA.

The present invention further contemplates genetic modulation of endogenous leptin levels to thereby induce modulation of osteoclastogenesis.

15

Although not intending to limit the present invention to any one theory or mode of action, it is proposed herein that leptin inhibits osteoclastogenesis by antagonism of the osteoclastic effect of ODF by stimulation of OPG and inhibition of RANK expression.

20 The preferred subject for treatment is a human. The invention extends, however, to treatment in non-human animals such as primates, livestock animals (e.g. sheep, cows, pigs, goats, donkeys, horses), laboratory test animals (e.g. mice, rats, guinea pigs, hamsters), companion animals (e.g. dogs, cats) and captive wild animals.

- 17 -

EXAMPLE 1

Human Peripheral Blood Mononuclear Cell (PBMC) Cultures

PBMC were isolated from the peripheral blood of haemochromatic patients and healthy
5 volunteers. Whole blood was spun at 700g and serum discarded. Blood cells were then
diluted 1:1 in PBS and layered over ficoll at a volume ratio of 5:3 and spun at 400 g for
30 min. The top layer was discarded and the underlying layer containing the peripheral
blood mononuclear cells (PBMCs) collected. PBMCs were washed in PBS to remove
ficoll, collected *via* centrifugation (140 g) and resuspended in eagle's MEM/10% v/v
10 FCS. PBMCs were seeded into 25 cm³ tissue flasks (20-25x10⁶ PBMCs/flask) and 4x4
mm cortical bovine bone slices (1x10⁶ PBMCs/bone slice) and left to adhere for 2 hrs.
Flasks and bone slices were rinsed to remove non-adherent cells and fresh media added.

EXAMPLE 2

15 *Action of Leptin*

The inventors proposed that systemic and/or bone marrow-derived leptin acted on
osteoclast precursors (directly and/or indirectly) and regulated osteoclastogenesis. The
inventors cultured adherent human peripheral blood monocytes (hPBMCs) on bone slices
20 for 21 days in the presence of ODF and M-CSF (Quinn, 1998) with and without added
leptin at various concentrations. The formation of multinuclear (MNC) osteoclasts was
quantified by cytochemical staining for tartrate-resistant acid phosphatase (TRAP), ¹²⁵I-
salmon calcitonin (¹²⁵I-sCT) autoradiography for calcitonin receptor (CTR) and the
identification of bone resorption lacunae by SEM.

25 The inventors found that leptin was a potent inhibitor of ODF-dependent osteoclast
(TRAP+ve, CTR+ve MNCs) formation (Figure 1 and Table 3) and that this effect was
dose-dependent (Figure 2). Consistent with this, was a corresponding dose-dependent
decrease in bone resorption (Figure 3). At the highest concentration used (1.6 µg/ml),
30 leptin reduced the number of osteoclasts and plan area of bone resorption by
approximately 80%.

- 18 -

Although not intending to limit the present invention to any one theory or mode of action, the inventors postulated that the mechanism of the antagonistic effect of leptin on ODF-induced osteoclast generation might be related to stimulation of ODF's decoy receptor, OPG and/or inhibition of its target cell receptor, RANK. To test this hypothesis, PBMCs were treated with increasing concentrations of leptin for 24h and OPG and RANK mRNA expression assessed by RT-PCR. It was found that leptin (0.032-3.2 μ g/ml) increased OPG mRNA and decreased RANK mRNA in a dose-dependent manner (Figure 4). The OPG and RANK PCR products were confirmed by restriction enzyme digest. (The OPG response will be confirmed by RNase protection assay and/or "real-time" PCR).

The inhibitory effect of leptin on osteoclast generation is also seen in co-cultures of osteoblast-like UMR 106-01 cells and PBMCs, which do not require the addition of ODF since it is produced by the UMR 106-01. Treatment of a number of osteoblast (rat calvarial, UMR 106-01, SAOs-2) and stromal (ST2, giant cell tumour, M3T3-L1) cells with leptin had no consistent effect on expression of OPG, ODF or RANK mRNA.

TABLE 3
EFFECT OF LEPTIN ON THE GENERATION OF CALCITONIN RECEPTOR
POSITIVE (CTR +ve) CELLS

Adherent PBMC's cultured on bone slices for 3 weeks in MEM/MCSF (25ng/ml) \pm ODF (30ng/ml) \pm Leptin (1.6 μ g/ml). Bone slices reacted for TRAP activity and calcitonin binding determined autoradiography.

Treatment	MNC, CTR+ve	Mono	Mono, CTR+ve
MCSF alone	0	1345 \pm 270	0
MCSF+ODF	367 \pm 50	55 \pm 9	16 \pm 4
MCSF+ODF+Leptin	0	1380 \pm 360	9 \pm 3



- 19 -

EXAMPLE 3

Gene Expression by Semi-Quantitative RT-PCR

Cultured cells were directly lysed in RNazol B solution and total RNA extracted according
5 to the manufacturer's instructions. For RT and PCR reactions, a Perkin Elmer / Cetus DNA
Thermal Cycler was used. Reverse transcription was performed in the presence of 5mM
MgCl₂, 1 mM deoxynucleotide mix, 3.2 mg random primers, 50 units RNase inhibitor and
20 units AMV reverse transcriptase. The final mixture was reacted at 25 C for 10 min, 42
C for 60 min and 95 C for 5 min to denature the enzyme.

10

Sense and antisense primers were designed using the MacVector program and synthesised
by Gibco BRL, (Gaithersburg, MD). Sequences and sizes are defined in Table 4.

TABLE 4

Gene	Forward Primer	Backward Primer	Product Size
GAPDH	5' CAGTCAGCCGCATCTTCTTTTG 3'	5' TGGTTCACACCCATGACGAAC 3'	464 bp
OPG	5' GTACGTCAAGCAGGAGTGCAATC 3'	5' TTCTTGTGAGCTGTGTTGCCG 3'	472 bp
RANK	5' TTAAGCCAGTGCTTCACGGG 3'	5' ACGTAGACCACGATGATGTCGC 3'	497 bp

PCR products were confirmed by restriction enzyme digest and all primer pairs spanned intron-exon splice sites allowing for the detection of mRNA only.

PCR amplification was performed with cycles of denaturation at 95 C for 1 min, annealing at 55 C for 2 min, and extension at 72 C for 1 min. The reaction mixture contained 40 pmol of each primer, 200 mM dNTPs, 2ml of 10X reaction buffer, optimised concentrations of MgCl₂; 0.75 mM (OPG), and 1.0 mM (GAPDH and Rank), 1U Taq DNA polymerase, and sterile distilled water up to 20 ml. The mixture was then overlayed with paraffin oil. For semi-quantitative RT-PCR analysis, the optimal number of cycles for each gene was determined as follows: GAPDH, 20 cycles, OPG, 32 cycles and Rank, 30 cycles. PCR products were resolved on a 1.2% w/v agarose gel and visualised using ethidium bromide. The size of the bands were confirmed by a 100 bp DNA ladder (Gibco BRL, Gaithersburg, MD). Complementary DNA from a sample of human giant cell tumour was used a positive control as we found it to express all the genes studied. Band intensities were measured on the Kodak Digital Science™ 1D Image Analysis Software and expressed as a ratio of GAPDH intensity.

EXAMPLE 4***Osteoclastogenesis assays employing purified CD14+ cells***

Leptin treatment does not significantly inhibit osteoclastogenesis in assays that use
5 highly purified CD14+ve cells cultured on bone slices for 21 days in the presence of ODF
and M-CSF. CD14+ve cells were positively-selected from PBMCs using anti-CD14
antibody-labelled immunomagnetic beads and the VarioMACs system. Purity (90-95%)
was confirmed with FACs analysis. CD14+ cells are highly efficient in the production of
osteoclasts. PBMC populations depleted of CD14+ve cells (i.e. CD14-ve) are not able to
10 generate osteoclasts in this assay (Figure 5).

Furthermore, leptin does not upregulate expression of OPG mRNA in purified CD14+ve
cells, although down-regulation of RANK mRNA is observed.

15 These results indicate that the mechanism of leptin-induced inhibition of
osteoclastogenesis is not via a direct effect of leptin on CD14+ cells, which appear to be
the predominant adherent osteoclast precursor present in the PBMC fraction.

Thus, leptin appears to be acting via another cell type(s) present in the PBMC fraction.
20 At this time the identity of this cell(s) is unknown.

The proposed mechanism of inhibition of osteoclast generation by leptin is shown in
Figure 6.

25 Those skilled in the art will appreciate that the invention described herein is susceptible
to variations and modifications other than those specifically described. It is to be
understood that the invention includes all such variations and modifications. The
invention also includes all of the steps, features, compositions and compounds referred
to or indicated in this specification, individually or collectively, and any and all
30 combinations of any two or more of said steps or features.



BIBLIOGRAPHY

Auwerx, J. *et al.* *The LANCET* 351: 737-742, 1998.

Bonner and Laskey *Eur. J. Biochem.* 46: 83, 1974.

Friedman, J. M. *et al.* *Nature* 395: 763-770, 1998.

Marmur and Doty *J. Mol. Biol.* 5: 109, 1962.

Matsuzaki, K. *et al.* *Biochem. Biophys. Res. Commun.* 246: 199-204, 1998.

Quinn J. M. *et al.* *Endocrinology* 139: 4424-4427, 1998.

Simonet, W.S. *et al.* *Cell* 89: 309-319, 1997.

Suda, T. *et al.* *Endocrine Reviews* 13: 66-80, 1992.

Suda, T *et al.* *Endocrine Reviews* 20: 345-357, 1999.

Yasuda, H. *et al.* *Endocrinology* 139: 1329-1337, 1998.

- 1 -

SEQUENCE LISTING

<110> THE UNIVERSITY OF MELBOURNE

<120> A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME

<130> EJH/AF

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.0

<210> 1

<211> 20

<212> DNA

<213> Human cells

<400> 1

ctactgcac agatccaagg

20

<210> 2

<211> 21

<212> DNA

<213> Human cells

<400> 2

gtcattggta ctggccaac t

21

<210> 3

<211> 24

<212> DNA

<213> Human cells

<400> 3

gcaatgcttt cactcctgag aaac

24

<210> 4

<211> 27

<212> DNA

<213> Human cells

<400> 4

cagtaaacac acagccacga caatgag

27

<210> 5



- 2 -

<211> 20
<212> DNA
<213> Human cells

<400> 5
catggagaag gctggggctc 20

<210> 6
<211> 20
<212> DNA
<213> Human cells

<400> 6
cactgacacg ttggcagtgg 20

<210> 7
<211> 504
<212> DNA
<213> Human cells

<220>
<221> CDS
<222> (1)..(501)

<400> 7
atg cat tgg gga acc ctg tgc gga ttc ttg tgg ctt tgg ccc tat ctt 48
Met His Trp Gly Thr Leu Cys Gly Phe Leu Trp Leu Trp Pro Tyr Leu
1 5 10 15
ttc tat gtc caa gct gtg ccc atc caa aaa gtc caa gat gac acc aaa 96
Phe Tyr Val Gln Ala Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys
20 25 30
acc ctc atc aag aca att gtc acc agg atc aat gac att tca cac acg 144
Thr Leu Ile Lys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr
35 40 45
cag tca gtc tcc tcc aaa cag aaa gtc acc ggt ttg gac ttc att cct 192
Gln Ser Val Ser Ser Lys Gln Lys Val Thr Gly Leu Asp Phe Ile Pro
50 55 60
ggg ctc cac ccc atc ctg acc tta tcc aag atg gac cag aca ctg gca 240
Gly Leu His Pro Ile Leu Thr Leu Ser Lys Met Asp Gln Thr Leu Ala
65 70 75 80
gtc tac caa cag atc ctc acc agt atg cct tcc aga aac gtg atc caa 288
Val Tyr Gln Gln Ile Leu Thr Ser Met Pro Ser Arg Asn Val Ile Gln
85 90 95

- 3 -

ata tcc aac gac ctg gag aac ctc cgg gat ctt ctt cac gtg ctg gcc 336
 Ile Ser Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Val Leu Ala
 100 105 110

ttc tct aag agc tgc cac ttg ccc tgg gcc agt ggc ctg gag acc ttg 384
 Phe Ser Lys Ser Cys His Leu Pro Trp Ala Ser Gly Leu Glu Thr Leu
 115 120 125

gac agc ctg ggg ggt gtc ctg gaa gct tca ggc tac tcc aca gag gtg 432
 Asp Ser Leu Gly Gly Val Leu Glu Ala Ser Gly Tyr Ser Thr Glu Val
 130 135 140

gtg gcc ctg agc agg ctg cag ggg tct ctg cag gac atg ctg tgg cag 480
 Val Ala Leu Ser Arg Leu Gln Gly Ser Leu Gln Asp Met Leu Trp Gln
 145 150 155 160

ctg gac ctc agc cct ggg tgc tga 504
 Leu Asp Leu Ser Pro Gly Cys
 165

<210> 8

<211> 167

<212> PRT

<213> Human cells

<400> 8

Met His Trp Gly Thr Leu Cys Gly Phe Leu Trp Leu Trp Pro Tyr Leu
 1 5 10 15

Phe Tyr Val Gln Ala Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys
 20 25 30

Thr Leu Ile Lys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr
 35 40 45

Gln Ser Val Ser Ser Lys Gln Lys Val Thr Gly Leu Asp Phe Ile Pro
 50 55 60

Gly Leu His Pro Ile Leu Thr Leu Ser Lys Met Asp Gln Thr Leu Ala
 65 70 75 80

Val Tyr Gln Gln Ile Leu Thr Ser Met Pro Ser Arg Asn Val Ile Gln
 85 90 95

Ile Ser Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Val Leu Ala
 100 105 110

Phe Ser Lys Ser Cys His Leu Pro Trp Ala Ser Gly Leu Glu Thr Leu
 115 120 125

Asp Ser Leu Gly Gly Val Leu Glu Ala Ser Gly Tyr Ser Thr Glu Val

- 4 -

130	135	140
Val Ala Leu Ser Arg Leu Gln Gly Ser Leu Gln Asp Met Leu Trp Gln		
145	150	155 160
Leu Asp Leu Ser Pro Gly Cys		
165		

<210> 9
 <211> 22
 <212> DNA
 <213> Human cells

<400> 9
 cagtcagccg catcttcttt tg 22

<210> 10
 <211> 21
 <212> DNA
 <213> Human cells

<400> 10
 tgggttcacac ccatgacgaa c 21

<210> 11
 <211> 23
 <212> DNA
 <213> Human cells

<400> 11
 gtacgtcaag caggagtga atc 23

<210> 12
 <211> 21
 <212> DNA
 <213> Human cells

<400> 12
 ttcttgtag ctgtgttgcc g 21

<210> 13
 <211> 20
 <212> DNA
 <213> Human cells

<400> 13

- 5 -

ttaagccagt gcttcacggg

20

<210> 14

<211> 22

<212> DNA

<213> Human cells

<400> 14

acgtagacca cgatgatgtc gc

22


DATED this 3rd day of August, 1999

THE UNIVERSITY OF MELBOURNE



By DAVIES COLLISON CAVE

Patent Attorneys for the Applicants

A



B



C





Figure 1




Figure 2





Figure 3.

A



B




Fig 4






Figure 5

Figure 6.



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.